Trinity Biotech Provides An Update On The Continued Development Of Its Continuous Glucose Monitor Technology; Says Recent Testing Of This Patented Process Has Confirmed Its Effectiveness In Improving The Performance Of Trinity Biotech's Glucose Biosensor
Trinity Biotech Provides An Update On The Continued Development Of Its Continuous Glucose Monitor Technology; Says Recent Testing Of This Patented Process Has Confirmed Its Effectiveness In Improving The Performance Of Trinity Biotech's Glucose Biosensor
Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on the continued development of its glucose biosensor technology. Earlier this year Trinity Biotech was granted a European patent (EP3703565) for a novel method that enhances the performance of an indwelling sensor, such as a glucose biosensor. Recent testing of this patented process has confirmed its effectiveness in improving the performance of Trinity Biotech's glucose biosensor. Trinity Biotech intends to use this breakthrough process to stabilise and improve the functionality of the glucose biosensor in its next generation continuous glucose monitor (CGM) technology.
Trinity Biotech plc（納斯達克股票代碼：TRIB）是一家商業階段的生物技術公司，專注於人類診斷和糖尿病管理解決方案，包括可穿戴生物傳感器，今天介紹了其葡萄糖生物傳感器技術持續發展的最新情況。今年早些時候，Trinity Biotech獲得了一項歐洲專利（EP3703565），該專利涉及一種增強葡萄糖生物傳感器等內住傳感器的性能的新方法。最近對這種專利工藝的測試證實了其在改善Trinity Biotech葡萄糖生物傳感器的性能方面的有效性。Trinity Biotech打算利用這一突破性工藝來穩定和改善其下一代連續葡萄糖監測（CGM）技術中葡萄糖生物傳感器的功能。
CGMs are small patch-like wearable medical devices that use biosensor wires under the skin to measure glucose in real-time. These devices are increasingly popular in diabetes management and health monitoring.
CGM 是類似貼片的小型可穿戴醫療設備，它使用皮膚下的生物傳感器線來實時測量葡萄糖。這些設備在糖尿病管理和健康監測中越來越受歡迎。
譯文內容由第三人軟體翻譯。